What the data actually shows
The CDC’s PrEP Guidelines Work Group reviewed evidence from two randomized controlled trials and found lenacapavir, administered as a twice-yearly injection, demonstrated high efficacy in reducing HIV infection risk, with safety data showing no significant concerns beyond mild to moderate injection-site reactions. Based on that evidence, twice-yearly injectable lenacapavir is now strongly recommended as a PrEP option for people who would benefit from it. For a prevention method that only requires two visits a year instead of a daily pill, that’s a meaningful shift in what adherence can realistically look like for a lot of people.
Prevention and transparency aren’t the same tool
It’s worth separating two things that sometimes get lumped together. PrEP is a prevention tool. It’s something you take to protect yourself. Sharing your verified status with a partner is a different thing entirely. It’s not about protecting yourself, it’s about giving someone else the same clarity you have, so they can make informed decisions too.
Both matter. Neither replaces the other. A great prevention tool doesn’t make the conversation about status unnecessary, and being open about status doesn’t reduce the value of prevention. They work together, the same way a seatbelt and a stop sign both matter on the same drive.
This is one of those things we don’t talk about often, but it’s worth saying plainly here: sharing your HIV status on Protecht has always been free, for everyone, with no subscription required. Not a trial. Not a limited-time offer. It’s a permanent part of how we built this.
Why HIV sharing is free on Protecht, always
- HIV status sharing is always free, no subscription needed
- Permanent, not a trial or promotion
- A values commitment, not a marketing feature
Everything else, the other conditions, the vaccination records, the advanced sharing controls, that’s part of Protecht+. But HIV sharing stays free. That’s not a marketing angle. It’s just how we think this should work.
Sources: Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis — United States, 2025, CDC Morbidity and Mortality Weekly Report. CDC Recommends New Injectable HIV PrEP, CDC director’s letter.
